Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).

ABSTRACT:

Objective

To describe the impact of omalizumab on asthma management in patients treated as part of normal clinical practice in the UK National Health Service (NHS).

Design

A non-interventional, mixed methodology study, combining retrospective and prospective data collection for 12 months pre-omalizumab and post-omalizumab initiation, respectively.

Setting

Data were collected in 22 UK NHS centres, including specialist centres and district general hospitals in the UK.

Participants

258 adult patients (aged ≥16 years; 65% women) with severe persistent allergic asthma treated with omalizumab were recruited, of whom 218 (84.5%) completed the study.

Primary and secondary outcome measures

The primary outcome measure was change in mean daily dose of oral corticos

SUBMITTER: Niven RM 

PROVIDER: S-EPMC4985870 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature